Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-LMO2 Antibody (R3G86)

Catalog #:   RHD68304 Specific References (39) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM
Accession: P25791
Overview

Catalog No.

RHD68304

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400

Target

RBTNL1, Rhombotin-2, T-cell translocation protein 2, LMO-2, Cysteine-rich protein TTG-2, TTG2, LIM domain only protein 2, LMO2, RHOM2, RBTN2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P25791

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3G86

Data Image
References

Single-cell profiling reveals monocyte heterogeneity and association with liver fibrosis in patients with chronic HBV., PMID:40227083

The LIM-domain-only protein LMO2 and its binding partner LDB1 are differentially required for class switch recombination., PMID:39847321

Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance., PMID:39374535

[Establishment and Clinical Significance of Prognostic Nomogram Model for Diffuse Large B-Cell Lymphoma Based on Immunohistochemistry Markers and International Prognostic Index Scores]., PMID:37356936

Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels., PMID:36358737

Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel., PMID:34945004

A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2., PMID:33837087

Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds., PMID:33794223

Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System., PMID:32187599

The life and death of the germinal center., PMID:31751845

Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model., PMID:30962539

KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas., PMID:29140403

Littoral cell angioma of the spleen: a study of 25 cases with confirmation of frequent association with visceral malignancies., PMID:27374010

Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP., PMID:27196819

Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles., PMID:26869285

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study., PMID:26071053

The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma., PMID:25701230

Intracellular antibody capture: A molecular biology approach to inhibitors of protein-protein interactions., PMID:24881582

Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex., PMID:24407558

Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients., PMID:24117687

Tissue microarray in a subset of South African patients with DLBCL., PMID:23942329

High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas., PMID:22776842

Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody., PMID:22394247

LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era., PMID:22066713

Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation., PMID:22009820

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy., PMID:21441466

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab., PMID:21135273

Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain., PMID:20980262

Evaluation of an enzyme-linked fluorescent assay for the detection of Listeria monocytogenes from food., PMID:20938093

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study., PMID:19786664

V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia., PMID:19455608

Selection of complementary single-variable domains for building monoclonal antibodies to native proteins., PMID:19208637

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab., PMID:18615101

An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions., PMID:18438427

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab., PMID:18086797

The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas., PMID:17038524

Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy., PMID:16864781

The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells., PMID:9707419

The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development., PMID:8033210

Datasheet

Document Download

Anti-LMO2 Antibody (R3G86).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-LMO2 Antibody (R3G86) [RHD68304]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only